Harbour BioMed Welcomes Dr. Yajie Li as New Chief Medical Officer

Harbour BioMed, a global biopharmaceutical company renowned for its innovative approach to discovering, developing, and commercializing novel antibody therapeutics, is thrilled to announce a pivotal enhancement to its leadership team. The company has officially appointed Dr. Yajie Li as its new Chief Medical Officer (CMO), a move poised to significantly accelerate its ambitious clinical development programs.

Dr.

Li brings an extraordinary depth of experience and a stellar track record in global clinical development, making her an invaluable addition to Harbour BioMed. Her illustrious career spans over two decades, during which she has held senior leadership roles at some of the world's most prestigious pharmaceutical giants, including AstraZeneca, Sanofi, and Novartis.

This diverse background has equipped her with a unique perspective and comprehensive expertise in advancing drug candidates from early-stage development through to successful regulatory submissions.

Her expertise is particularly strong in critical therapeutic areas such as oncology and autoimmune diseases – fields where Harbour BioMed has a robust and promising pipeline.

Dr. Li's profound understanding of clinical strategy, regulatory affairs, and global drug development will be instrumental in guiding Harbour BioMed's innovative therapies through crucial development milestones and ultimately bringing them to patients worldwide who are in urgent need of better treatment options.

Dr.

Jingsong Wang, Founder, Chairman, and Chief Executive Officer of Harbour BioMed, expressed immense enthusiasm regarding the appointment. "We are incredibly excited to welcome Dr. Yajie Li to our leadership team. Her exceptional clinical development expertise and proven leadership in global pharmaceutical settings are precisely what Harbour BioMed needs as we continue to advance our innovative pipeline," Dr.

Wang stated. "Dr. Li's appointment is a strategic step that will undoubtedly accelerate our mission to deliver transformative therapies for patients suffering from severe diseases."

Echoing this sentiment, Dr. Yajie Li shared her excitement about joining the dynamic team. "I am honored and thrilled to join Harbour BioMed, a company at the forefront of biopharmaceutical innovation," said Dr.

Li. "I look forward to leveraging my experience to contribute to the acceleration of the company's clinical programs and to help bring truly life-changing treatments to patients globally. The opportunity to work with such a dedicated and visionary team is incredibly inspiring."

This strategic appointment underscores Harbour BioMed's unwavering commitment to scientific excellence and its relentless pursuit of groundbreaking medical solutions.

With Dr. Li at the helm of its medical operations, the company is exceptionally well-positioned to navigate the complexities of clinical development and fulfill its promise of delivering next-generation therapeutics to patients in need.